Skip to main
SANA
SANA logo

Sana Biotechnology (SANA) Stock Forecast & Price Target

Sana Biotechnology (SANA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Sana Biotechnology Inc. is demonstrating a strengthened outlook for its therapeutic platforms, notably increasing the probability of success in its Type 1 Diabetes (T1D), fusogen, and autoimmune disease platforms, potentially reflecting a more favorable landscape for product development. The company’s favorable safety profile for its products, particularly UP421, combined with significant efficacy indicators, positions it well to attract interest as it prepares for significant upcoming data releases and a cash position of $152.5 million further supports operational stability and growth potential. Moreover, expected decreases in expenditures due to the strategic prioritization of core programs indicate effective resource management, enhancing the overall financial health and future prospects of the company.

Bears say

Sana Biotechnology Inc faces a challenging financial outlook due to anticipated substantial operating losses that may persist indefinitely, raising concerns about the company's ability to achieve profitability. The company is burdened by a higher-than-expected SG&A expense of $17.3 million and R&D expenses totaling $47 million, both exceeding previous estimates, which compounds financial strain. Furthermore, significant risks related to clinical trial success, competition, regulatory approvals, and the need for extensive future financing—which is projected to be around $1.4 billion through 2041—cast further doubt on the potential for positive stock price movement despite any operational achievements.

Sana Biotechnology (SANA) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sana Biotechnology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sana Biotechnology (SANA) Forecast

Analysts have given Sana Biotechnology (SANA) a Buy based on their latest research and market trends.

According to 8 analysts, Sana Biotechnology (SANA) has a Buy consensus rating as of Jul 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sana Biotechnology (SANA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.